Literature DB >> 28284558

A step forward for patients with NRAS-mutant melanoma.

Michael A Postow1, Paul B Chapman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28284558      PMCID： PMC5540131          DOI： 10.1016/S1470-2045(17)30172-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

1.  Regulation of Raf-1 by direct feedback phosphorylation.

Authors:  Michele K Dougherty; Jürgen Müller; Daniel A Ritt; Ming Zhou; Xiao Zhen Zhou; Terry D Copeland; Thomas P Conrads; Timothy D Veenstra; Kun Ping Lu; Deborah K Morrison
Journal:  Mol Cell       Date:  2005-01-21       Impact factor: 17.970

2.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Authors:  Paolo A Ascierto; Dirk Schadendorf; Carola Berking; Sanjiv S Agarwala; Carla Ml van Herpen; Paola Queirolo; Christian U Blank; Axel Hauschild; J Thaddeus Beck; Annie St-Pierre; Faiz Niazi; Simon Wandel; Malte Peters; Angela Zubel; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

3.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

4.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Authors:  Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-28       Impact factor: 11.205

5.  Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.

Authors:  Lawrence N Kwong; James C Costello; Huiyun Liu; Shan Jiang; Timothy L Helms; Aliete E Langsdorf; David Jakubosky; Giannicola Genovese; Florian L Muller; Joseph H Jeong; Ryan P Bender; Gerald C Chu; Keith T Flaherty; Jennifer A Wargo; James J Collins; Lynda Chin
Journal:  Nat Med       Date:  2012-09-16       Impact factor: 53.440

6.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Authors:  Meghna Das Thakur; Fernando Salangsang; Allison S Landman; William R Sellers; Nancy K Pryer; Mitchell P Levesque; Reinhard Dummer; Martin McMahon; Darrin D Stuart
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

7.  Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Authors:  Sonya C Tate; Teresa F Burke; Daisy Hartman; Palaniappan Kulanthaivel; Richard P Beckmann; Damien M Cronier
Journal:  Br J Cancer       Date:  2016-03-15       Impact factor: 7.640
  7 in total
  1 in total

1.  Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.

Authors:  Patricia Reyes-Uribe; Maria Paz Adrianzen-Ruesta; Zhong Deng; Ileabett Echevarria-Vargas; Ilgen Mender; Steven Saheb; Qin Liu; Dario C Altieri; Maureen E Murphy; Jerry W Shay; Paul M Lieberman; Jessie Villanueva
Journal:  Oncogene       Date:  2018-04-26       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.